The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia

References

• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
   PubMed Web of Science ®Google Scholar
• Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML 201 study. Blood. 2011;117:2358–2365.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125:3878–3885.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31:3360–3368.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–1259.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of elderly patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–2677.
   PubMed Web of Science ®Google Scholar
• Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nature Rev Mol Cell Biol. 2002;3:430–440.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. DNA topoisomerase ii and its growing repertoire of biological functions. Nature Rev Cancer. 2009;9:327–337.
   PubMed Web of Science ®Google Scholar
• Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol. 2000;64:221–253.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Rev Cancer. 2009;9:338–350.
   PubMed Web of Science ®Google Scholar
• Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001;32(Suppl.1):S9–S15.
   PubMed Web of Science ®Google Scholar
• Tomita K, Tsuzuki Y, Shibamori K, et al. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 1. J Med Chem. 2002;45:5564–5575.
   PubMed Web of Science ®Google Scholar
• Aldred KJ, Schwanz HA, Li G, et al. The activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions. Biochemistry. 2015;54:1278–1286.
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Tomita K, Shibamori K, et al. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem. 2004;47:2097–2109.
   PubMed Web of Science ®Google Scholar
• Walsby EJ, Coles SJ, Knapper S, et al. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. 2011;96:393–399.
   PubMed Web of Science ®Google Scholar
• Hawtin RE, Stockett DE, Byl JA, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. Plos One. 2010;5:e10186.
   PubMed Web of Science ®Google Scholar
• Hoch U, Lynch J, Sato Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009;64:53–65.
   PubMed Web of Science ®Google Scholar
• Scatena CD, Kumer JL, Arbitrario JP, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010;66:881–888.
   PubMed Web of Science ®Google Scholar
• Stockett DE, Kumer JL, Scatena CD, et al. Voreloxin is synergistic in in vitro combination with cytarabine and additive in combination with azacitidine, decitabine and clofarabine. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 15-19, 2009, Boston, Massachusetts.
   Google Scholar
• Lancet JE, Ravandi F, Ricklis RM, et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011;25:1808–1814.
   PubMed Web of Science ®Google Scholar
• Evanchik MJ, Allen D, Yoburn JC, et al. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8,-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos. 2009;37:594–601.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Roboz GJ, Cripe LD, et al. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015;100:231–237.
   PubMed Web of Science ®Google Scholar
• Stuart RK, Cripe LD, Maris MB, et al. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in elderly poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015;168:796–805.
   PubMed Web of Science ®Google Scholar
• Daver N, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed elderly patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Haematologica. 2016;101(s1):187 (Abstr S505).
   PubMed Web of Science ®Google Scholar
• Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16:1025–1036.
   PubMed Web of Science ®Google Scholar
• Dennis M, Russell N, Hills RK, et al. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in elderly patients with acute myeloid leukemia. Blood. 2015;125:2923–2932.
   PubMed Web of Science ®Google Scholar
• Advani RH, Hurwitz HI, Gordon MS, et al. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res 2010; 16:2167–2175.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Ritchie EK, Sayar H, et al. Durable overall survival benefit in patients ≥ 60 years with relapsed or refractory AML treated with vosaroxin/cytarabine vs placebo/cytarabine: updated results from the Valor trial. Blood. 2016;128(issue22):abstr903.
   Google Scholar
• Yu TW, Anderson D. Reactive oxygen species-induced DNA damage and its modification: a chemical investigation. Mutation Res. 1997;379:201–210.
   PubMed Web of Science ®Google Scholar
• Doroshow JH, Synold TW, Somlo G, et al. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood. 2001;97:2839–2845.
   PubMed Web of Science ®Google Scholar
• Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487–494.
   PubMed Web of Science ®Google Scholar
• Zhang H, Fang H, Wang K. Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Invest. 2014;1:13.
   PubMedGoogle Scholar